Aurobindo Pharma arm CuraTeQ Biologics to commercialize proposed biosimilar to Stelara Ruchika Sharma8 July 2023 12:00 PM ISTCuraTeQ intends to file this product in India and Emerging Markets as early as in 2024 and the regulated markets filing is expected to begin in 2026.
Breast cancer biosimilar product meets primary endpoint in Phase 3 clinical trial: Aurobindo Pharma Ruchika Sharma5 July 2023 11:30 AM ISTHyderabad:Aurobindo Pharma Limited has announced that the breast cancer biosimilar product, BP02 (Trastuzumab or biosimilar to Herceptin), developed ...
Aurobindo Pharma to sell shares in Auro Vaccines to Curateq Biologics Ruchika Sharma29 May 2023 2:48 PM ISTHyderabad: The Board of Directors of Aurobindo Pharma Limited has approved the sale and transfer of all equity shares held by the Company in...
Aurobindo Pharma plans to infuse around Rs 300 crore for biologics manufacturing facilities Ruchika Sharma2 Sept 2022 12:11 PM ISTThe board approved entering into contract manufacturing operations (CMO) for biologicals for effective utilisation of capacities.
Aurobindo arm, Orion expand licensing deal to commercialize biosimilars pipeline in select European markets Ruchika Sharma12 Jan 2022 1:18 PM ISTHyderabad: Aurobindo Pharma Limited (along with its subsidiaries together referred to as "Aurobindo") has announced that its subsidiary CuraTeQ...
Aurobindo Pharma arm submits first biosimilar filing with EMA Ruchika Sharma23 Sept 2021 10:00 AM ISTHyderabad: Drugmaker, Aurobindo Pharma Limited, has recently announced that the company's subsidiary CuraTeQ Biologics Pvt Ltd. has submitted...
